Read the Psychiatric Times February 2020 issue cover-to-cover, with a bonus PDF.
When we find ourselves in the half-tested world of off-label therapies, what’s a psychiatrist to do?
Over the past two decades, deaths associated with alcohol abuse have increased, but little data point to demographic changes.
My hacker stole my identity crisis.
Access to care has improved—especially for low-income and vulnerable populations—which has resulted in better health outcomes.
Drug companies are investing more to study psychiatric disorders, and there may be novel treatments in the near future.
A hypothetical first conversation with a non-binary person . . . One of us would be feeling nervous and the other certain—a phenomenon not unfamiliar to a psychiatrist, only here the roles would be reversed.
A phone rings on stage like a flashback and we return to our fantasy that characters can die and revive, that the show must go on . . .
Although 6 months is the recommended duration for buprenorphine treatment, many patients discontinue within a few weeks or months of treatment.
James L. Knoll IV, MD, analyzes the ethical and legal duties of psychiatrists treating substance use disorders.